论文部分内容阅读
[目的]评价癌胚抗原(CEA)、细胞角蛋白19片段(CYFRA21-1)、神经元特异性烯醇化酶(NSE)3项肿瘤标志物在肺癌不同病理类型及治疗前后的表达意义。[方法]用电化学发光法分别测定246例肺癌,其中腺癌108例、鳞癌70例以及68例小细胞未分化肺癌(SCLC)患者化疗前后血清CEA、CYFRA21-1和NSE的水平。[结果]3项肿瘤标志物在肺癌不同病理类型中比较均有差异,其中腺癌CEA水平均高于其他类型(P<0.01),鳞癌CYFRA21-1水平高于其他类型(P<0.01),小细胞肺癌NSE水平高于其他类型(P<0.01)。治疗有效的肺癌患者治疗后3项标志物水平均明显下降,而治疗无效者治疗前后均无明显变化或升高。[结论]3项肿瘤标志物水平在腺癌、鳞癌及小细胞肺癌检测中均明显升高,在治疗有效组化疗后显著下降,提示此三种指标的测定有助于肺癌预后评估和疗效判定。
[Objective] To evaluate the expression of three tumor markers of CEA, CYFRA21-1 and NSE before and after different pathological types of lung cancer. [Methods] The levels of serum CEA, CYFRA21-1 and NSE in 246 cases of lung cancer, including 108 cases of adenocarcinoma, 70 cases of squamous cell carcinoma and 68 cases of small cell lung cancer (SCLC) were measured by electrochemiluminescence. [Results] The three tumor markers were different in different pathological types of lung cancer. CEA level in adenocarcinoma was higher than other types (P <0.01), and the level of CYFRA21-1 in squamous cell carcinoma was higher than other types (P <0.01) , And the level of NSE in small cell lung cancer was higher than other types (P <0.01). After treatment of lung cancer patients with effective treatment of the three markers were significantly decreased, while the treatment of ineffective no significant change or increase before and after treatment. [Conclusion] The levels of three tumor markers in adenocarcinoma, squamous cell carcinoma and small cell lung cancer were significantly increased in the treatment group after chemotherapy was significantly decreased, suggesting that the determination of these three indicators contribute to lung cancer prognosis assessment and efficacy determination.